

[Back to Contents](#)

TSH Secreting Tumors Can Be Cured By Long Term Octreotide Treatment

Fliers E, et al.

during several years after stopping treatment without recurrence. A similar course is known for other pituitary tumors, most typically for prolactinomas, that may be definitely cured with conservative treatment (4).

It is interesting that several conservatively treated TSHomas have been followed by other groups without surgical intervention (3). It is not known whether some of these patients have been taken off treatment without recurrence of the tumor. Possibly some of

these cases will join the list started by the present case of being cured after long-term drug treatment. Obviously, the question remains whether one of the two treatments, octreotide or dopaminergic agents, has superior efficacy. To my knowledge this is not known. The number of published cases of TSHomas is still small, and it is certainly advisable to treat these patients with great prudence.

— Albert G. Burger MD

REFERENCES

1. Refetoff S, Weiss RE, Usala SJ. The syndromes of resistance to thyroid hormone. *Endocr Rev* 1993;14:348-99.
2. Refetoff S. Resistance to thyroid hormone: one of several defects causing reduced sensitivity to thyroid hormone. *Nat Clin Pract Endocrinol Metab* 2008;4:1.
3. Kienitz T, Quinkler M, Strasburger CJ, Ventz M. Long-term management in five cases of TSH-secreting pituitary adenomas: a single center study and review of the literature *Eur J Endocrinol* 2007;157:39-46.
4. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. *N Engl J Med* 2003;349:2023-33.